EGFR and lung adenocarcinoma: Although the rates of EGFR amplification were reported higher in lung adenocarcinoma patients with 19del than those with L858R mutations (15, 16), the present study found that EGFR amplification was present at similar percentages, being detected in 40% (8/20) of patients with 19del and 35% (10/29) of patients with L858R mutations (Figure 2B).